EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of acute porphyrias The importance of the follow up of patients and carriers



Treatment of acute porphyrias The importance of the follow up of patients and carriers



Orvosi Hetilap 144(19): 933-938, Majus 11



Acute porphyrias are caused by the inherited decreased activity of the enzymes of the heme biosynthesis pathway. Depending on the affected enzyme there are 4 types of them: acute intermittent porphyria, porphyria variegata, coproporphyria and delta-aminolevulinic acid dehydratase deficient porphyria, listed in order of their frequency. Basically the clinical picture is the same in the four types of acute porphyria. The most frequent complaints and symptoms are: cramping abdominal pain, nausea, vomiting, muscle weakness of the limbs then, in the advanced phase, there is a red-colored urine, hyponatremia, subileus, acute psychosis and Landry-type paralysis. Without proper treatment death is caused by respiratory paralysis or serious arrhythmia. In case of suspicion of acute porphyria it is mandatory to identify the type of the acute porphyria and the actual status of the patient. The later indicates what kind of treatmen should be used. In the acute phase the early therapy with heme arginate is the treatment of choice. Since the clinical symptoms are precipitated by endogenous or exogenous inducing factors - most often by drugs -, the drugs negatively affecting the heme biosynthesis should be omitted at once even in the suspicion of acute porphyria. The role of the inducing factors in the manifestation of the clinical symptoms makes possible the prevention. It is possible to avoid the inducing factors and this way to prevent the acute attack if the acute porphyrias are recognized in time and the patients and the carriers are under regular control. The patients receive special identification card and the up-to-date list of safe drugs. They can use only these drugs in any kind of illness. Other drugs should be considered as porphyrinogenic since it is impossible to predict based on their chemical structure if they negatively affect the heme biosynthesis.

(PDF 0-2 workdays service: $29.90)

Accession: 035980805

Download citation: RISBibTeXText



Related references

Treatment of acute porphyrias. The importance of follow-up of patients and carriers. Orvosi Hetilap 144(19): 933-938, 2003

The activities of the enzymes of haem biosynthesis in the porphyrias and during treatment of acute intermittent porphyrias. International Journal of Biochemistry 12(5-6): 941-946, 1980

The Diagnostic Importance Of Faecal Porphyrins In The Differentiation Of The Porphyrias. Ii. Values In The Cutaneous Porphyrias. South African Journal of Laboratory and Clinical Medicine. Suid-Afrikaanse Tydskrif Vir Laboratorium- en Kliniekwerk 18: 126-134, 1963

Porphyrins, porphyrin metabolism and porphyrias. II. Diagnosis and monitoring in the acute porphyrias. Scandinavian Journal of Clinical and Laboratory Investigation 60(7): 541-559, 2001

Porphyrins, porphyrin metabolism and porphyrias. II. Diagnosis and monitoring in the acute porphyrias. Scandinavian Journal of Clinical & Laboratory Investigation 60(7): 541-560, November, 2000

Sorbent therapy of the porphyrias oral sorbents for the acute porphyrias. American Journal of Human Genetics 37(4 SUPPL): A19, 1985

Follow-up of patients with chronic hepatitis B infection with no indication for treatment. Ultrasound follow-up for carriers of the hepatitis B surface antigen. Gastroenterologia Y Hepatologia 37 Suppl 2: 26-29, 2016

Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium. American Journal of Medicine 127(12): 1233-1241, 2015

Diagnosis and treatment of acute porphyrias. Gematologiya i Transfuziologiya 37(11-12): 33-40, 1992

Recommendations for the diagnosis and treatment of the acute porphyrias. Annals of Internal Medicine 142(6): 439-450, 2005

Reanimation And Value Of Recent Treatment Of Acute Porphyrias. Bulletins et Memoires de la Societe Medicale des Hopitaux de Paris 115: 1135-1143, 1964

Hematin in the treatment of acute hepatic porphyrias. Der Internist 20(9): 454-455, 1979

The place of resuscitation in the treatment of acute porphyrias. Marseille Medical 104(6): 573-576, 1967

Acute hepatic porphyrias. Detection, prophylaxis and treatment. Materia Medica Polona. Polish Journal of Medicine and Pharmacy 28(1): 5-7, 1996